Group 1 - *ST Jinglan has been issued a "Notice of Case Filing" by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, marking a recurrence of such issues since July 2023 [2] - The company has previously faced penalties for multiple disclosure violations, including failure to disclose goodwill impairment in annual reports for 2021 and 2022, resulting in a fine of 3 million yuan [2] - The company has committed to improving internal governance and enhancing the quality of information disclosure to protect the interests of shareholders [2] Group 2 - *ST Jinglan's main business includes industrial and urban solid waste harmless disposal and soil environment remediation, but its performance has been declining [3] - Revenue has decreased from 738 million yuan in 2021 to 195 million yuan in 2022, and further down to 149 million yuan in 2023, a year-on-year decline of 23.69% [3] - Although revenue is projected to increase to 378 million yuan in 2024, the company is expected to incur a net loss of 110 million yuan, a year-on-year increase of 110.41% [3] Group 3 - In Q1 2025, *ST Jinglan reported revenue of 126 million yuan and a net loss of 12.95 million yuan [4] - The company attributed the Q1 loss to production stoppages during the Spring Festival, which significantly reduced profits due to depreciation, labor, and interest costs [4] - Annual maintenance costs also contributed to the reduced profits, leading to a pattern of low or negative profits in the first quarter of each year [4]

Group 1 - The core point of the news is that Jinglan Technology Co., Ltd. (*ST Jinglan) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may not significantly impact its daily operations [1] - In 2024, *ST Jinglan reported an operating income of approximately 378 million yuan, a year-on-year increase of 153.69%, but still recorded a net loss of about 110 million yuan [2] - The company has experienced continuous losses over four years from 2019 to 2022, with net losses of 1.037 billion yuan in 2019, 2.355 billion yuan in 2020, 1.275 billion yuan in 2021, and 1.356 billion yuan in 2022 [2] Group 2 - *ST Jinglan has a history of information disclosure violations, having received an administrative penalty from the CSRC in November 2023 for failing to disclose goodwill impairment information in its 2021 and 2022 annual reports [3] - The former chairman and president of *ST Jinglan, along with the financial officer, were held responsible for the inaccuracies in the financial reports, leading to penalties from the CSRC [3]

据查，2019 年 8 月至 2020 年 10 月，朱明虬及其一致行动人昌吉州首创投资有限合伙企业，将思美传 媒 29.99% 股份转让给四川旅投。双方签订的《收购备忘录》及补充协议明确约定：若 2019 年度实际 审计净利润低于 2.5 亿元，朱明虬需在审计报告公告后三个月内，以现金方式向上市公司补足差额。作 为当时的控股股东与实控人，朱明虬及四川旅投明知该业绩补偿条款属于重大信息，却蓄意隐瞒、未依 法履行告知义务，直至 2023 年 12 月 23 日才通过《相关协议补充披露的公告》公开。此行为严重违反 《上市公司信息披露管理办法》第三条中信息披露义务人及时传递信息的规定。 2023 年 11 月 27 日，思美传媒在深交所互动易平台回复投资者提问时，声称 "抖音超市现阶段由本公司 代运营"，该表述致使公司股价午后开盘即涨停。然而当日收盘后，公司却改口称仅代运营抖音官方超 市的单个直播间；次日，抖音电商官方微博公开辟谣，证实思美传媒此前言论与事实严重不符。根据 《上市公司信息披露管理办法》第二十一条，上市公司在投资者关系活动中不得作出误导性陈述，思美 传媒上述行为已构成典型的信披违规。 （文章来源：21 ...

Core Viewpoint - Wuhan Yifei Laser Co., Ltd. received a warning letter from the Hubei Securities Regulatory Bureau due to significant discrepancies in its financial disclosures, particularly regarding its 2024 annual report and the previously released performance forecast [1][2][3]. Financial Discrepancies - The company reported a net profit attributable to shareholders of 24.32 million yuan for 2024, a decrease of 75.94% compared to 2023, without providing a performance forecast for 2024 [1][2]. - The initial performance announcement on February 28, 2025, indicated a net profit of 71.37 million yuan, which was later corrected to 2.43 million yuan in the annual report, highlighting a significant reporting error [2]. Regulatory Actions - The Hubei Securities Regulatory Bureau issued a warning letter to the company and its key executives, including the chairman and CFO, for failing to fulfill their disclosure obligations as per the regulations [2][3]. - The warning letter serves as an administrative regulatory measure and will be recorded in the securities and futures market integrity archives [3]. Internal Control Issues - The company's 2024 financial report received a negative opinion from the auditing firm, leading to the implementation of additional risk warnings on its stock starting May 6, 2025 [7][8]. - The company is required to disclose progress on resolving these issues at least once a month during the risk warning period [7][8]. Measures Taken - The company is actively cooperating with the auditing firm to provide additional evidence and is enhancing its internal control systems to prevent future discrepancies [9][10]. - Recent board meetings have led to the revision of governance and fundraising management policies to strengthen oversight and compliance [9][10]. Commitment to Compliance - The company emphasizes the importance of training its board members and key personnel on relevant laws and regulations to improve governance and operational standards [10]. - Ongoing communication with regulatory authorities is prioritized to ensure compliance and transparency in operations [10].

Group 1 - ST Baili (603959) closed at 4.13 yuan on May 30, 2025, up 5.09% from the previous week, with a market cap of 2.025 billion yuan, ranking 37th in the professional engineering sector and 4880th in the A-share market [1] - The company received an administrative penalty notice from the Hunan Regulatory Bureau of the China Securities Regulatory Commission (CSRC) regarding contract violations with seven suppliers, totaling prepayments of 191.91 million yuan, which were misappropriated for personal debts [1] - The CSRC plans to impose a fine of 4 million yuan on ST Baili and additional fines on individuals involved, including 600,000 yuan on Wang Hairong, 80,000 yuan on Wang Wei, and 50,000 yuan on Yu Lanjian, along with a three-year market ban for Wang Hairong [1] Group 2 - The company stated that the penalties do not trigger major violations that would lead to mandatory delisting, and its production and operations remain normal [1] - ST Baili plans to enhance internal governance and improve the quality of information disclosure following the penalties [1]

Core Viewpoint - The company, Zhenbao Island, faced criticism from the Shanghai Stock Exchange for failing to timely disclose a significant transaction that generated a net profit of approximately 420 million yuan, which accounted for 227% of its audited net profit for 2022 [1][2][3] Group 1: Transaction Details - The undisclosed transaction involved the sale of 100% equity of its subsidiary, Hulin Fangsheng Pharmaceutical Technology Co., which was sold for 425 million yuan to Heilongjiang Hehui Pharmaceutical Co. [2][3] - The transaction's profit exceeded the threshold requiring shareholder approval and timely disclosure, as it represented over 50% of the company's audited net profit for the previous year [2][3] Group 2: Regulatory Issues - This is not the first instance of Zhenbao Island facing issues related to information disclosure; the company has received warnings and criticisms from regulators multiple times in the past two years for similar violations [4] - In April 2024, the company was issued a warning by the Heilongjiang Securities Regulatory Bureau for failing to disclose a related party transaction involving 80 million yuan in non-operating fund occupation [4] Group 3: Financial Performance - Zhenbao Island reported revenues of 4.2 billion yuan, 3.1 billion yuan, and 2.7 billion yuan for the years 2022, 2023, and 2024 respectively, with a net profit of 753 million yuan in Q1 of the current year, down from 2.9 billion yuan in the same period last year [5] - The decline in Q1 performance was attributed to the postponement of the third batch of national traditional Chinese medicine procurement, which affected sales and profits [5]

华中数控：未按规定披露2024年度业绩预告 公司及相关责任人收到湖北证监局警示函 智通财经5月30日电，华中数控(300161.SZ)公告称，公司于近日收到湖北证监局出具的《警示函》，指 出公司未按规定披露2024年度业绩预告，违反了《上市公司信息披露管理办法》的相关规定。陈吉红、 田茂胜、万欣、陈程作为公司及相关责任人，未履行勤勉尽责义务，对公司上述违规行为负有主要责 任。湖北证监局决定对公司、陈吉红、田茂胜、万欣、陈程采取出具警示函的行政监管措施，并记入证 券期货市场诚信档案。公司及相关责任人将吸取教训，加强学习和执行相关法律法规，防范类似问题再 次出现，持续提升信息披露质量。 ...

Core Viewpoint - Jiangying Pharmaceutical, a long-established pharmaceutical company, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][4]. Company Overview - Jiangying Pharmaceutical primarily engages in the research, production, and sales of traditional Chinese medicine and was listed on the A-share market in December 2007 [2][11]. - The company has experienced overall poor operating performance since its listing, with a cumulative profit of only 275 million yuan over 18 years and only five cash dividends totaling less than 90 million yuan [2][12]. Financial Performance - In the first quarter of 2023, the company reported a net profit attributable to shareholders of 15.4 million yuan, a nearly twofold increase year-on-year, but still low compared to its historical performance [2][12]. - The company's revenue for the first quarter was 122 million yuan, reflecting a year-on-year growth of 28.83% [12]. - However, the company faced a significant cash flow issue, with a net operating cash flow of -11.83 million yuan, a decline of 193.73% year-on-year [12]. Research and Development - Jiangying Pharmaceutical's R&D expenses have significantly decreased, with only 6.76 million yuan allocated for R&D in 2024 [3][13]. - The company has consistently invested between 10 million and 15 million yuan in R&D from 2015 to 2023, with a notable drop in 2024 [13]. Management Changes - The company's financial director, Shi Junping, resigned after only 10 months in the position, which raises concerns about management stability [5][6]. - Shi's previous experience includes roles in tax planning and accounting, but he had not held any prior positions within Jiangying Pharmaceutical [7][8]. Regulatory Issues - Jiangying Pharmaceutical has a history of regulatory violations, including multiple warnings and penalties from the CSRC for issues related to information disclosure and performance predictions [8][9][10].

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission, leading to a significant drop in its stock price following the announcement of the investigation [1][2]. Group 1: Company Background - Jiaying Pharmaceutical is an established pharmaceutical company known for its research, production, and sales of traditional Chinese medicine, with key products including throat and cold medications [3]. - The company experienced a major shareholder restructuring in 2024 when Hunan Yantianhe Pharmacy acquired 7% of Jiaying's shares for a total of 355 million yuan [1]. Group 2: Recent Developments - The company faced regulatory scrutiny after its independent director, Li Shanwei, was found to have violated disclosure regulations by selling shares during a sensitive period without proper notice [2]. - Jiaying disclosed that it had engaged in non-compliant related party transactions, with a total of approximately 235 million yuan transferred to related parties, including 170 million yuan to a subsidiary of Yantianhe [2][3]. - In the fourth quarter of 2024, Jiaying reported a revenue decline of 25.3%, with total annual revenue falling to 376 million yuan, a year-on-year decrease of 29.46% [3].

此外，独立董事李善伟的违规行为也令人咋舌。2024年12月，李善伟因隐瞒持股信息并在内幕信息敏感 期违规减持股票，被广东证监局采取责令购回违规减持股份的行政监管措施。其行为严重违反了信息披 露相关规定，损害了市场的公平性和投资者的利益。 嘉应制药此前还出现了多名高管职务异动，无疑给公司带来了更大的不确定性。 关联交易不规范是嘉应制药的一大问题。2024年第四季度，公司与养天和大药房股份有限公司及其关联 公司发生多笔关联交易，涉及金额高达1039.94万元，却未及时履行审议程序和披露，直至2025年4月才 补充披露。这种不规范操作严重损害了信息披露的及时性和准确性，让投资者难以及时了解公司的真实 经营状况。 资金管理漏洞同样严重。2024年9月至2025年1月期间，嘉应制药被关联方湖南药聚能医药有限公司非经 营性占用资金2.35亿元，且通过"月初转出、月末前转回"的方式粉饰痕迹，直至2025年1月23日才全部 归还。这种行为不仅违反了资金管理规定，也暴露了公司内部治理的混乱。 每经评论员 杜宇 5月28日晚间，嘉应制药（SZ002198，前收盘价：6.70元，市值：34亿元）公告因涉嫌信息披露违法违 规被证监会 ...